Chu J, Schweid A I, Weiss N S
Am J Obstet Gynecol. 1982 Jul 1;143(5):569-73. doi: 10.1016/0002-9378(82)90549-x.
In order to determine the role of postmenopausal estrogen use in survival of patients with endometrial cancer, we identified, through a population-based tumor registry serving the area, all white women in King County, Washington, aged 50 to 74, who developed endometrial cancer between January, 1975, and April, 1976 (N = 363). Estrogen use prior to diagnosis and survival status were ascertained through personal interview, medical records of private physicians, and registry follow-up data. The 4-year relative survival ratio in estrogen users was 1.05 compared to 0.898 in nonusers. Overall, after adjustment for age, the survival in estrogen users was significantly better than in nonusers (chi 2 = 30.5; p much less than 0.0001). While estrogen use may predispose to an increased incidence of endometrial cancer, it appears that such use does not lead to increased mortality from this condition.
为了确定绝经后使用雌激素对子宫内膜癌患者生存率的影响，我们通过为该地区服务的基于人群的肿瘤登记处，识别出了华盛顿州金县所有年龄在50至74岁之间、于1975年1月至1976年4月期间患子宫内膜癌的白人女性（N = 363）。通过个人访谈、私人医生的病历以及登记处的随访数据确定诊断前的雌激素使用情况和生存状况。雌激素使用者的4年相对生存率为1.05，而非使用者为0.898。总体而言，在调整年龄后，雌激素使用者的生存率显著高于非使用者（卡方 = 30.5；p远小于0.0001）。虽然使用雌激素可能会使子宫内膜癌的发病率增加，但似乎这种使用并不会导致因该疾病而增加死亡率。
